Skip to main content
Top
Published in: Clinical Pharmacokinetics 1/2013

01-01-2013 | Review Article

Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools

Authors: Aline Fuchs, Chantal Csajka, Yann Thoma, Thierry Buclin, Nicolas Widmer

Published in: Clinical Pharmacokinetics | Issue 1/2013

Login to get access

Abstract

Therapeutic drug monitoring (TDM) aims to optimize treatments by individualizing dosage regimens based on the measurement of blood concentrations. Dosage individualization to maintain concentrations within a target range requires pharmacokinetic and clinical capabilities. Bayesian calculations currently represent the gold standard TDM approach but require computation assistance. In recent decades computer programs have been developed to assist clinicians in this assignment. The aim of this survey was to assess and compare computer tools designed to support TDM clinical activities. The literature and the Internet were searched to identify software. All programs were tested on personal computers. Each program was scored against a standardized grid covering pharmacokinetic relevance, user friendliness, computing aspects, interfacing and storage. A weighting factor was applied to each criterion of the grid to account for its relative importance. To assess the robustness of the software, six representative clinical vignettes were processed through each of them. Altogether, 12 software tools were identified, tested and ranked, representing a comprehensive review of the available software. Numbers of drugs handled by the software vary widely (from two to 180), and eight programs offer users the possibility of adding new drug models based on population pharmacokinetic analyses. Bayesian computation to predict dosage adaptation from blood concentration (a posteriori adjustment) is performed by ten tools, while nine are also able to propose a priori dosage regimens, based only on individual patient covariates such as age, sex and bodyweight. Among those applying Bayesian calculation, MM-USC*PACK© uses the non-parametric approach. The top two programs emerging from this benchmark were MwPharm© and TCIWorks. Most other programs evaluated had good potential while being less sophisticated or less user friendly. Programs vary in complexity and might not fit all healthcare settings. Each software tool must therefore be regarded with respect to the individual needs of hospitals or clinicians. Programs should be easy and fast for routine activities, including for non-experienced users. Computer-assisted TDM is gaining growing interest and should further improve, especially in terms of information system interfacing, user friendliness, data storage capability and report generation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Buclin T, Gotta V, Fuchs A, et al. Monitoring drug therapy. Br J Clin Pharmacol. 2012;73(6):917–23.PubMedCrossRef Buclin T, Gotta V, Fuchs A, et al. Monitoring drug therapy. Br J Clin Pharmacol. 2012;73(6):917–23.PubMedCrossRef
2.
go back to reference Platt DR. Individualization of drug dosage regimens. Clin Lab Med. 1987;7(2):289–99.PubMed Platt DR. Individualization of drug dosage regimens. Clin Lab Med. 1987;7(2):289–99.PubMed
4.
go back to reference Burton M, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics & pharmacodynamics. principles of therapeutic drug monitoring. 4th edn. Baltimore: Lippincott Williams & Wilkins; 2006. Burton M, Shaw LM, Schentag JJ, Evans WE, editors. Applied pharmacokinetics & pharmacodynamics. principles of therapeutic drug monitoring. 4th edn. Baltimore: Lippincott Williams & Wilkins; 2006.
5.
go back to reference Durieux P, Trinquart L, Colombet I, et al. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 2008;3:CD002894. Durieux P, Trinquart L, Colombet I, et al. Computerized advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 2008;3:CD002894.
6.
go back to reference Kunz J, Shortliffe EH, Buchanan BG, et al. Computer-assisted decision making in medicine. J Med Philos. 1984;9(2):135–60.PubMedCrossRef Kunz J, Shortliffe EH, Buchanan BG, et al. Computer-assisted decision making in medicine. J Med Philos. 1984;9(2):135–60.PubMedCrossRef
7.
go back to reference Bates D, Soldin SJ, Rainey PM, et al. Strategies for physician education in therapeutic drug monitoring. Clin Chem. 1998;44(2):401–7.PubMed Bates D, Soldin SJ, Rainey PM, et al. Strategies for physician education in therapeutic drug monitoring. Clin Chem. 1998;44(2):401–7.PubMed
8.
go back to reference Anderson PO. Clinical pharmacokinetics computer programs. In: Anderson PO, McGuinness SM, Bourne PE, editors. Pharmacy informatics. Boca Raton: CRC Press Inc.; 2010. p. 199–216. Anderson PO. Clinical pharmacokinetics computer programs. In: Anderson PO, McGuinness SM, Bourne PE, editors. Pharmacy informatics. Boca Raton: CRC Press Inc.; 2010. p. 199–216.
9.
10.
go back to reference Special report: health care and technology. Medicine goes digital. The Economist 2009 Apr 16. Special report: health care and technology. Medicine goes digital. The Economist 2009 Apr 16.
11.
go back to reference Guiducci C, Temiz Y, Leblebici Y, et al. Integrating Bio-sensing functions on CMOS chips. 2010 Asia Pacific Conference on Circuits and Systems, Kuala Lumpur, 6–9 Dec 2010. Guiducci C, Temiz Y, Leblebici Y, et al. Integrating Bio-sensing functions on CMOS chips. 2010 Asia Pacific Conference on Circuits and Systems, Kuala Lumpur, 6–9 Dec 2010.
12.
go back to reference Buffington DE, Lampasona V, Chandler MHH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet. 1993;25(3):205–16.PubMedCrossRef Buffington DE, Lampasona V, Chandler MHH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet. 1993;25(3):205–16.PubMedCrossRef
13.
go back to reference Lenert LA, Klostermann H, Coleman RW, et al. Practical computer-assisted dosing for aminoglycoside antibiotics. Antimicrob Agents Chemother. 1992;36(6):1230–5.PubMedCrossRef Lenert LA, Klostermann H, Coleman RW, et al. Practical computer-assisted dosing for aminoglycoside antibiotics. Antimicrob Agents Chemother. 1992;36(6):1230–5.PubMedCrossRef
14.
go back to reference Peck CC, Sheiner LB, Martin CM, et al. Computer-assisted digoxin therapy. N Engl J Med. 1973;289(9):441–6.PubMedCrossRef Peck CC, Sheiner LB, Martin CM, et al. Computer-assisted digoxin therapy. N Engl J Med. 1973;289(9):441–6.PubMedCrossRef
15.
go back to reference Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411–59.PubMedCrossRef Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411–59.PubMedCrossRef
16.
go back to reference Hatton RC, Gotz VP, Robinson JD, et al. Conversion from intravenous aminophylline to sustained-release theophylline: computer simulation versus in vivo results. Clin Pharm. 1983;2 (4):347–52. Hatton RC, Gotz VP, Robinson JD, et al. Conversion from intravenous aminophylline to sustained-release theophylline: computer simulation versus in vivo results. Clin Pharm. 1983;2 (4):347–52.
17.
go back to reference Gougnard T, Charlier C, Plomteux G. “CAPCIL”: posologic adjustment of aminoglycoside treatments [in French]. Acta Clin Belg Suppl. 1999;1:17–9.PubMed Gougnard T, Charlier C, Plomteux G. “CAPCIL”: posologic adjustment of aminoglycoside treatments [in French]. Acta Clin Belg Suppl. 1999;1:17–9.PubMed
18.
go back to reference Lacarelle B, Pisano P, Gauthier T, et al. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation. Int J Biomed Comput. 1994;36(1–2):127–30.PubMedCrossRef Lacarelle B, Pisano P, Gauthier T, et al. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation. Int J Biomed Comput. 1994;36(1–2):127–30.PubMedCrossRef
19.
go back to reference Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22(3):155–63.PubMedCrossRef Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992;22(3):155–63.PubMedCrossRef
21.
go back to reference Jelliffe RW. The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care. 1991;922–4. Jelliffe RW. The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care. 1991;922–4.
22.
go back to reference Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol. 1997;43(2):125–35.PubMedCrossRef Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol. 1997;43(2):125–35.PubMedCrossRef
23.
go back to reference Robinson JD, Hatton RC, Russell WL, et al. Accuracy of serum gentamicin concentration predictions generated by a personal-computer software system. Clin Pharm. 1984 Sep-Oct;3(5):509–16. Robinson JD, Hatton RC, Russell WL, et al. Accuracy of serum gentamicin concentration predictions generated by a personal-computer software system. Clin Pharm. 1984 Sep-Oct;3(5):509–16.
24.
go back to reference Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci. 2011;32(2):72–81.PubMedCrossRef Sim SC, Ingelman-Sundberg M. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci. 2011;32(2):72–81.PubMedCrossRef
25.
go back to reference Gervasini G, Benitez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755–74.PubMedCrossRef Gervasini G, Benitez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755–74.PubMedCrossRef
26.
go back to reference Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761–804.PubMedCrossRef Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761–804.PubMedCrossRef
28.
go back to reference Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metab Drug Interact. 2004;20(4):195–217.CrossRef Fujita K. Food-drug interactions via human cytochrome P450 3A (CYP3A). Drug Metab Drug Interact. 2004;20(4):195–217.CrossRef
29.
go back to reference Corti N, Taegtmeyer AB. Clinically important food-drug interactions: what the practitioner needs to know [in German]. Praxis. 2012;101(13):849–55.PubMedCrossRef Corti N, Taegtmeyer AB. Clinically important food-drug interactions: what the practitioner needs to know [in German]. Praxis. 2012;101(13):849–55.PubMedCrossRef
30.
go back to reference Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet. 2006;45(4):365–83.PubMedCrossRef Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet. 2006;45(4):365–83.PubMedCrossRef
31.
go back to reference Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002;16(4):253–62.PubMedCrossRef Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002;16(4):253–62.PubMedCrossRef
32.
go back to reference Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new ‘multiple model’ dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet. 1998;34(1):57–77.PubMedCrossRef Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new ‘multiple model’ dosage design, Bayesian feedback and individualised target goals. Clin Pharmacokinet. 1998;34(1):57–77.PubMedCrossRef
33.
go back to reference Debord J, Voultoury JC, Lachatre G, et al. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients. Int J Biomed Comput. 1994;36(1–2):135–7.PubMedCrossRef Debord J, Voultoury JC, Lachatre G, et al. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients. Int J Biomed Comput. 1994;36(1–2):135–7.PubMedCrossRef
34.
go back to reference Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28(8):743–51.PubMedCrossRef Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28(8):743–51.PubMedCrossRef
35.
go back to reference Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008;48(9):1081–91.PubMedCrossRef Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008;48(9):1081–91.PubMedCrossRef
36.
go back to reference Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. Ther Drug Monit. 2012;34(4):368–77.PubMedCrossRef Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. Ther Drug Monit. 2012;34(4):368–77.PubMedCrossRef
37.
go back to reference Wright DF, Duffull SB. Development of a Bayesian forecasting method for warfarin dose individualization. Pharm Res. 2011;28(5):1100–11.PubMedCrossRef Wright DF, Duffull SB. Development of a Bayesian forecasting method for warfarin dose individualization. Pharm Res. 2011;28(5):1100–11.PubMedCrossRef
38.
go back to reference Bjorkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia. 2011;17(1):e239–40.PubMedCrossRef Bjorkman S. Evaluation of the TCIWorks Bayesian computer program for estimation of individual pharmacokinetics of FVIII. Haemophilia. 2011;17(1):e239–40.PubMedCrossRef
39.
40.
go back to reference Neef C, Jelliffe RW, van Laar T, et al. Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. Int J Biomed Comput. 1994;36(1–2):143–50.PubMedCrossRef Neef C, Jelliffe RW, van Laar T, et al. Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. Int J Biomed Comput. 1994;36(1–2):143–50.PubMedCrossRef
41.
go back to reference Gauthier T, Lacarelle B, Marre F, et al. Predictive performance of two software packages (USC*PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients. Int J Biomed Comput. 1994;36(1–2):131–4.PubMedCrossRef Gauthier T, Lacarelle B, Marre F, et al. Predictive performance of two software packages (USC*PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients. Int J Biomed Comput. 1994;36(1–2):131–4.PubMedCrossRef
42.
go back to reference Norris RL, Martin JH, Thompson E, et al. Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. Ther Drug Monit. 2010;32(5):615–23.PubMedCrossRef Norris RL, Martin JH, Thompson E, et al. Current status of therapeutic drug monitoring in Australia and New Zealand: a need for improved assay evaluation, best practice guidelines, and professional development. Ther Drug Monit. 2010;32(5):615–23.PubMedCrossRef
44.
go back to reference Gotta V, Widmer N, Montemurro M, et al. Therapeutic drug monitoring of imatinib: bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51(3):187–201.PubMedCrossRef Gotta V, Widmer N, Montemurro M, et al. Therapeutic drug monitoring of imatinib: bayesian and alternative methods to predict trough levels. Clin Pharmacokinet. 2012;51(3):187–201.PubMedCrossRef
45.
go back to reference Ensom MH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34(4):265–79.PubMedCrossRef Ensom MH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clin Pharmacokinet. 1998;34(4):265–79.PubMedCrossRef
46.
go back to reference Touw D, Neef C, Thomson AH, et al. Cost-effectiveness of therapeutic drug monitoring: an update. EJHP Sci. 2007;13(4):83–91. Touw D, Neef C, Thomson AH, et al. Cost-effectiveness of therapeutic drug monitoring: an update. EJHP Sci. 2007;13(4):83–91.
47.
go back to reference Shenfield GM. Therapeutic drug monitoring beyond 2000. Br J Clin Pharmacol. 2001;52(Suppl 1):3S–4S.PubMed Shenfield GM. Therapeutic drug monitoring beyond 2000. Br J Clin Pharmacol. 2001;52(Suppl 1):3S–4S.PubMed
48.
go back to reference Murphy JE, Slack MK, Campbell S. National survey of hospital-based pharmacokinetic services. Am J Health Syst Pharm. 1996;53(23):2840–7.PubMed Murphy JE, Slack MK, Campbell S. National survey of hospital-based pharmacokinetic services. Am J Health Syst Pharm. 1996;53(23):2840–7.PubMed
49.
go back to reference Pedersen CA, Schneider PJ, Santell JP, et al. ASHP national survey of pharmacy practice in acute care settings: monitoring, patient education, and wellness–2000. Am J Health Syst Pharm. 2000;57(23):2171–87.PubMed Pedersen CA, Schneider PJ, Santell JP, et al. ASHP national survey of pharmacy practice in acute care settings: monitoring, patient education, and wellness–2000. Am J Health Syst Pharm. 2000;57(23):2171–87.PubMed
50.
go back to reference Elin RJ. Computer-assisted therapeutic drug monitoring. Clin Lab Med. 1987;7(2):485–92.PubMed Elin RJ. Computer-assisted therapeutic drug monitoring. Clin Lab Med. 1987;7(2):485–92.PubMed
51.
go back to reference Nieuwlaat R, Connolly SJ, Mackay JA, et al. Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision maker-researcher partnership systematic review. Implement Sci. 2011;6:90. Nieuwlaat R, Connolly SJ, Mackay JA, et al. Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision maker-researcher partnership systematic review. Implement Sci. 2011;6:90.
52.
53.
go back to reference Special report: health care and technology. Fantastic voyage: technology is making health care more portable, precise and personal. The Economist 2009 Apr 16. Special report: health care and technology. Fantastic voyage: technology is making health care more portable, precise and personal. The Economist 2009 Apr 16.
Metadata
Title
Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools
Authors
Aline Fuchs
Chantal Csajka
Yann Thoma
Thierry Buclin
Nicolas Widmer
Publication date
01-01-2013
Publisher
Springer International Publishing AG
Published in
Clinical Pharmacokinetics / Issue 1/2013
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-012-0020-y

Other articles of this Issue 1/2013

Clinical Pharmacokinetics 1/2013 Go to the issue